Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder

Drug and Alcohol Dependence

Volumn 149, Issue , 2015, Pages 225-231

  Wilder, Christine ^a,b   Lewis, Daniel ^a   Winhusen, Theresa ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Medication assisted treatment; Methadone; Opioid use disorder; Patient dropout; Postpartum; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HISPANIC; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MEDICATION ASSISTED TREATMENT DISCONTINUATION; OPIATE ADDICTION; PERINATAL DEATH; PERINATAL PERIOD; PREGNANCY; PREGNANT WOMAN; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; RETROSPECTIVE STUDY; RISK FACTOR; SELECTIVE ABORTION; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; KAPLAN MEIER METHOD; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; STATISTICS AND NUMERICAL DATA;

BUPRENORPHINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES;

EID: 84926211015     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.02.012     Document Type: Article

References (47)

1. American Congress of Obstetricians and Gynecologists ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012, 119:1070-1076. 10.1097/AOG.0b013e318256496e.
2. Bao Y., Liu Z., Epstein D., Du C., Shi J., Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am. J. Drug Alcohol Abuse 2009, 35:28-33. 10.1080/00952990802342899.
3. Brady T., Salvucci S., Sverdlov L., Male A., Kyeyune H., Sikali E., DeSale S., Yu P. Methadone dosage and retention: an examination of the 60mg/day threshold. J. Addict. Dis. 2005, 24:23-47.
4. Burns L., Mattick R., Lim K., Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007, 102:264-270.
5. Chappel J., Senay E. Special treatment problems in a drug abuse program. Proc. Natl. Conf. Methadone Treat. 1973, 2:1098-1104.
6. Cox J., Allard R., Maurais E., Haley N., Small C. Predictors of methadone program non-retention for opioid analgesic dependent patients. J. Subst. Abuse Treat. 2013, 44:52-60. 10.1016/j.jsat.2012.03.002.
7. Crandall C., Crosby R., Carlson G. Does pregnancy affect outcome of methadone maintenance treatment?. J. Subst. Abuse Treat. 2004, 26:295-303.
8. Dakof G., Quille T., Tejeda M., Alberga L., Bandstra E., Szapocznik J. Enrolling and retaining mothers of substance-exposed infants in drug abuse treatment. J. Consult. Clin. Psychol. 2003, 71:764-772.
9. Dansky B., Byrne C., Brady K. Intimate violence and post-traumatic stress disorder among individuals with cocaine dependence. Am. J. Drug Alcohol Abuse 1999, 25:257-268.
10. Deck D., Carlson M. Retention in publicly funded methadone maintenance treatment in two Western States. J. Behav. Health Serv. Res. 2005, 32:43-60.
11. DePetrillo P., Rice J. Methadone dosing and pregnancy: impact on program compliance. Int. J. Addict. 1995, 30:207-217.
12. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. 2003, ACD002208. 10.001002/14651858.CD14002208.
13. Fajemirokun-Odudeyi O., Sinha C., Tutty S., Pairaudeau P., Armstrong D., Phillips T., Lindow S.W. Pregnancy outcome in women who use opiates. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 126:170-175. 10.1016/j.ejogrb.2005.08.010.
14. Fischer G., Eder H., Jagsch R., Lennkh C., Habeler A., Aschauer H., et al. Maintenance therapy with synthetic opioids within a multidisciplinary program - a stabilizing necessity for pregnant opioid dependent women. Arch Womens Ment Health. 1998, 1:109-116. 10.1007/s007370050014.
15. Fitzsimons H., Tuten M., Vaidya V., Jones H. Mood disorders affect drug treatment success of drug-dependent pregnant women. J. Subst. Abuse Treat. 2007, 32:19-25.
16. Greenfield L., Brady J., Besteman K., De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996, 42:125-131.
17. Haller D., Knisely J., Elswick R., Dawson K., Schnoll S.H. Perinatal substance abusers: factors influencing retention. J. Subst. Abuse Treat. 1997, 14:513-519.
18. Holbrook A., Kaltenbach K. Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression. Am. J. Drug Alcohol Abuse 2012, 38:575-579. 10.3109/00952990.2012.696168.
19. Hulse G., Milne E., English D., Holman C. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 1998, 93:1033-1042.
20. Jones H., Haug N., Silverman K., Stitzer M., Svikis D.S. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 2001, 61:297-306. 10.1016/S0376-8716(00)00152-6.
21. Jones H., Heil S., Baewert A., Arria A., Kaltenbach K., Martin P., et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012, 107(Suppl. 1):5-27. 10.1111/j.1360-0443.2012.04035.x.
22. Jones H., Johnson R., Jasinski D., O'Grady K., Chisholm C., Choo R., Crocetti M., Dudas R., Harrow C., Huestis M.A., Jansson L.M., Lantz M., Lester B.M., Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005, 79:1-10. 10.1016/j.drugalcdep.2004.11.013.
23. Jones H., Kaltenbach K., Heil S., Stine S., Coyle M., Arria A., O'Grady K.E., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:23202331. 10.1056/NEJMoa1005359.
24. Jones H., Svikis D., Tran G. Patient compliance and maternal/infant outcomes in pregnant drug-using women. Subst. Use Misuse 2002, 37:1411-1422.
25. Kandall S., Doberczak T., Jantunen M., Stein J. The methadone-maintained pregnancy. Clin. Perinatol. 1999, 26:173-183.
26. Kelly S., O'Grady K., Mitchell S., Brown B., Schwartz R. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011, 117:170-175. 10.1016/j.drugalcdep.2011.01.008.
27. Kissin W., Svikis D., Morgan G., Haug N. Characterizing pregnant drug-dependent women in treatment and their children. J. Subst. Abuse Treat. 2001, 21:27-34.
28. Laken M., Ager J. Effects of case management on retention in prenatal substance abuse treatment. Am. J. Drug Alcohol Abuse 1996, 22:439-448.
29. Laken M.P., McComish J.F., Ager J. Predictors of prenatal substance use and birth weight during outpatient treatment. J. Subst. Abuse Treat. 1997, 14:359-366. 10.1016/s07405472(96)00006-2.
30. Ludlow J., Evans S., Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust. N. Z. J. Obstet. Gynaecol. 2004, 44:302-306. 10.1111/j.1479-828X.2004.00221.x.
31. MacGowan R., Swanson N., Brackbill R., Rugg D., Barker T., Molde S. Retention in methadone maintenance treatment programs, Connecticut and Massachusetts, 1990-1993. J. Psychoactive Drugs 1996, 28:259-265.
32. Magura S., Nwakeze P., Demsky S. Pre-and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93:51-60.
33. Mattick R., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, 10.1002/14651858.CD002209.pub2.
34. McCarthy J., Leamon M., Parr M., Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am. J. Obstet. Gynecol. 2005, 193:606-610. 10.1016/j.ajog.2005.03.072.
35. McGuire F. Arrest record and retention in methadone maintenance treatment. Int. J. Addict. 1979, 14:1009-1013.
36. Minozzi S., Amato L., Bellisario C., Ferri M., Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst. Rev. 2013, 12:CD006318. 10.1002/14651858.CD006318.pub3.
37. Newman R., Tytun A., Bashkow S. Retention of patients in the New York City methadone maintenance treatment program. Int. J. Addict. 1976, 11:905-931.
38. Peles E., Adelson M. Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic. J. Addict. Dis. 2006, 25:39-45.
39. Peles E., Schreiber S., Bloch M., Dollberg S., Adelson M. Duration of methadone maintenance treatment during pregnancy and pregnancy outcome parameters in women with opiate addiction. J. Addict. Med. 2012, 6:18-23. 10.1097/ADM.0b013e318229bb25.
40. Silverman K., Svikis D., Robles E., Stitzer M., Bigelow G. A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp. Clin. Psychopharmacol. 2001, 9:14-23.
41. Substance Abuse and Mental Health Services Administration Results from the 2002 National Survey on Drug Use and Health: National Findings. NHSDA Series H-22, HHS Publication No. (SMA) 03-3836 2003, Substance Abuse and Mental Health Services Administration, Rockville, MD.
42. Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: National Findings. NHSDA Series H-46, HHS Publication No. (SMA) 13-4795 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
43. Substance Abuse and Mental Health Services Administration Treatment Episode Data Set (TEDS): 2011. Discharges from Substance Abuse Treatment Services. BHSIS Series S-70, HHS Publication No. (SMA) 14-4846 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD.
44. Substance Abuse and Mental Health Services Administration 2011 Opioid Treatment Program Survey: Data on Substance Abuse Treatment Facilities with OTPs. BHSIS Series S-65, HHS Publication No. (SMA) 14-4807 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD.
45. Svikis D., Lee J., Haug N., Stitzer M. Attendance incentives for outpatient treatment: effects in methadone-and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend. 1997, 48:33-41.
46. Tuten M., Svikis D., Keyser-Marcus L., O'Grady K., Jones H. Lessons learned from a randomized trial of fixed and escalating contingency management schedules in opioid-dependent pregnant women. Am. J. Drug Alcohol Abuse 2012, 38:286-292. 10.3109/00952990.2011.643977.
47. Welle-Strand G.K., Skurtveit S., Jones H.E., Waal H., Bakstad B., Bjarko L., Ravndal E. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a new National Cohort Study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013, 127:200-206.